---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034714"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:40:44.676195+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation

## Summary
- Pre-money equity value of Aspire approximately $316 million.
- Combined company to be named 'Aspire Biopharma Holdings, Inc.' and list on Nasdaq under 'ASPH'.
- Existing Aspire shareholders expected to retain majority ownership after closing.
- Expected closing end of Q4 2024 or beginning of Q1 2025; subject to regulatory and stockholder approvals.
- Aspire's lead product Instaprin (soluble aspirin) targeting 505(b)(2) NDA with FDA.

## SEC filing metadata
- accession: 0001493152-24-034714
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/0001493152-24-034714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034714
- JSON: https://secwatch.observer/filing/0001493152-24-034714.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.